Pfizer Inc.
PFEPfizer Inc. is a global pharmaceutical company known for its research and development of innovative medicines and vaccines. Founded in 1849, it has a diverse portfolio that includes treatments for various medical conditions, and it played a key role in developing one of the first COVID-19 vaccines. Pfizer operates in multiple healthcare sectors, including biopharmaceuticals, oncology, and immunology.
Dividend History
Investors can expect a dividend payout of $0.43 per share, scheduled to be distributed in 59 days on March 6, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 6, 2026 | $0.43 | 2026-01-23 | 2026-01-23 |
| December 1, 2025 | $0.43 | 2025-11-07 | 2025-11-07 |
| September 2, 2025 | $0.43 | 2025-07-25 | 2025-07-25 |
| June 13, 2025 | $0.43 | 2025-05-09 | 2025-05-09 |
| March 7, 2025 | $0.43 | 2025-01-24 | 2025-01-24 |
Dividends Summary
- Pfizer Inc. has issued 89 dividend payments over the past 22 years
- The most recent dividend was paid 36 days ago, on December 1, 2025
- The highest dividend payed out to investors during this period was $0.43 per share
- The average dividend paid during this period was $0.30 per share.
Company News
Motley Fool contributors review 2025's best and worst performing stocks. Nice list includes Alphabet, Nvidia, MercadoLibre, TJX Companies, and Klarna for strong execution and growth. Naughty list features Fiserv, The Trade Desk, Target, and Starbucks due to poor performance and company-specific challenges. Contributors discuss investment opportun...
With the S&P 500 trading at elevated valuations (26x forward earnings vs. 20-year average of 16x), the article identifies three undervalued stocks poised for potential gains: Comcast (trading at 6.84x P/E with strong broadband margins and upcoming sports broadcasting rights), Micron Technology (29x earnings with 57% revenue growth despite tech se...
Major pharmaceutical companies are planning price increases on at least 350 branded medicines in 2026, with a median increase of about 4%. This includes vaccines and cancer therapies, despite pressure from the Trump administration to control drug costs. Only nine drugs will see price cuts, including Jardiance which faces a 40%+ reduction followin...
The global celiac disease market is experiencing significant growth driven by rising awareness of gluten-related disorders, improved diagnostic technologies, and expanding gluten-free product offerings. Key drivers include increased prevalence, advancements in diagnostics, and emerging pharmacological therapies. However, challenges such as high c...
